USA - NASDAQ:BIOX - KYG1117K1141 - Common Stock
2025 (2025-6-30) | 2024 (2024-6-30) | 2023 (2023-6-30) | 2022 (2022-6-30) | 2021 (2021-6-30) | ||||
---|---|---|---|---|---|---|---|---|
Revenue | 333.30M | 464.80M | 415.10M | 328.40M | 206.70M | |||
Minority Interest Expense | 3.40M | -3.00M | -1.39M | -3.30M | -3.00M | |||
Cost Of Goods | 203.40M | 278.20M | 235.46M | 208.40M | 118.60M | |||
Gross Profit | 129.90M | 186.60M | 179.64M | 120.00M | 88.10M | |||
Operating Expenses | 133.00M | 142.30M | 127.26M | 87.60M | 53.50M | |||
Research and Development | N/A | 10.64M | 9.89M | 4.10M | 4.00M | |||
Selling, General, and Administrative Expenses | N/A | 113.51M | 101.87M | 72.80M | 44.40M | |||
Operating Income | -3.10M | 44.30M | 52.37M | 32.40M | 34.60M | |||
Interest Income/Expense | -52.50M | -33.20M | -22.59M | -16.80M | -20.20M | |||
Other Income/Expense | N/A | 0.00 | -11.29M | -7.90M | -6.60M | |||
Non Recurring Items | 1.80M | 0.00 | 610.60K | 6.40M | 2.80M | |||
Income Before Taxes | -53.80M | 11.10M | 19.11M | 14.10M | 10.50M | |||
Income Tax | 1.30M | 3.80M | -1.07M | 18.00M | 14.40M | |||
Net Income | -51.80M | 4.30M | 18.78M | -7.20M | -6.90M | |||
EBITDA | N/A | 65.60M | 71.77M | 41.59M | 40.87M | |||
Per Share Data | ||||||||
EPS Diluted Total Ops | -0.82 | 0.07 | 0.30 | -0.17 | -0.18 | |||
Non GAAP EPS | -0.80 | 0.06 | 0.25 | -0.14 | -0.18 | |||
Statistics | ||||||||
Gross Profit Margin | 38.97% | 40.15% | 43.28% | 36.54% | 42.62% | |||
Profit Margin | -15.54% | 0.93% | 4.52% | -2.19% | -3.34% | |||
Operating Profit Margin | -0.93% | 9.53% | 12.62% | 9.87% | 16.74% |
All data in USD